Treatment to Adult Patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen

Descriptions

NHS AGEM CSU on behalf of NHS England Specialised Commissioning is inviting suitably qualified and experienced providers to deliver treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the drug nusinersen under a compliance process specified in Document 1 of the process documentation.On 24.7.2019, NICE published technology appraisal guidance on the use of the drug nusinersen to treat adult patients with 5q Spinal muscular atrophy (SMA). NHS England has agreed a ‘Managed Access Agreement (MAA)’ for the drug nusinersen for the treatment of eligible patients with SMA. The NICE guidance sets out that the drug should only be made available to people who meet the criteria for treatment under the associated MAA.The key objectives of the compliance process: to commission service to serve adult patients eligible to receive the treatment nationally. It is estimated that 600 patients (adults and children) will be treated in England over the lifetime of the contract.